KR20150050595A - 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 - Google Patents
저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 Download PDFInfo
- Publication number
- KR20150050595A KR20150050595A KR1020157010213A KR20157010213A KR20150050595A KR 20150050595 A KR20150050595 A KR 20150050595A KR 1020157010213 A KR1020157010213 A KR 1020157010213A KR 20157010213 A KR20157010213 A KR 20157010213A KR 20150050595 A KR20150050595 A KR 20150050595A
- Authority
- KR
- South Korea
- Prior art keywords
- dose
- diclofenac
- beta
- cyclodextrin
- formulations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960001259 diclofenac Drugs 0.000 title claims abstract description 59
- 229920000858 Cyclodextrin Polymers 0.000 title claims abstract description 23
- 235000011175 beta-cyclodextrine Nutrition 0.000 title claims abstract description 16
- 239000001116 FEMA 4028 Substances 0.000 title claims abstract description 14
- 229960004853 betadex Drugs 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title claims description 46
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 title description 45
- 238000009472 formulation Methods 0.000 title description 42
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 title description 10
- -1 diclofenac compound Chemical class 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- 208000002193 Pain Diseases 0.000 claims description 40
- 230000036407 pain Effects 0.000 claims description 35
- 229960001193 diclofenac sodium Drugs 0.000 claims description 5
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 5
- 230000000007 visual effect Effects 0.000 claims description 3
- 206010002091 Anaesthesia Diseases 0.000 abstract description 13
- 230000037005 anaesthesia Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 description 16
- 239000003814 drug Substances 0.000 description 13
- 229940079593 drug Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 9
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 6
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 230000002688 persistence Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000283086 Equidae Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 229930194542 Keto Natural products 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229940097362 cyclodextrins Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000272470 Circus Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 208000004550 Postoperative Pain Diseases 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 208000005298 acute pain Diseases 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-UHFFFAOYSA-N alpha-D-glucopyranose Natural products OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 125000001309 chloro group Chemical class Cl* 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZEKANFGSDXODPD-UHFFFAOYSA-N glyphosate-isopropylammonium Chemical compound CC(C)N.OC(=O)CNCP(O)(O)=O ZEKANFGSDXODPD-UHFFFAOYSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical group OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004384 ketorolac tromethamine Drugs 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- RZSCFTDHFNHMOR-UHFFFAOYSA-N n-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]pyridine-3-carboxamide;1,1-dimethyl-3-(4-propan-2-ylphenyl)urea Chemical compound CC(C)C1=CC=C(NC(=O)N(C)C)C=C1.FC1=CC(F)=CC=C1NC(=O)C1=CC=CN=C1OC1=CC=CC(C(F)(F)F)=C1 RZSCFTDHFNHMOR-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000004357 third molar Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
도 2는 제형의 mg에 걸쳐 관찰된 통증상실 피크(mm VAS)에 대한 복용량-반응 곡선을 도시한다. 디클로페낙 및 케토롤락 제형 양자가 시험되었다.
도 3은 단일 복용량 상태에서 재-치료에 대한 중앙 시간(시)을 사용하여 시험된 복용량-지속성 상관관계를 도시한다. 디클로페낙의 두 제형이 시험되었다.
도 4는 디클로페낙의 복용량(mg)에 의한 NSAID 부작용을 갖는 환자의 백분율을 도시한다.
처리군 | 결과 | 최대 효과 % |
플라시보 | 62.8(SEM 9) | 17% |
DIC 3.75mg | 134.1(SEM 8) | 38% |
DIC 9.4mg | 237.6(SEM 15) | 68% |
DIC 18.75mg | 284.4(SEM 21) | 82% |
DIC 37.5mg | 348.2(SEM 30) | 100% |
DIC 75mg | 346.3(SEM 27) | 100% |
케토롤락 | 400.3(SEM 36) | 100% |
Claims (5)
- 대상자에게 이들의 필요에 따라 무통각을 제공하는 비경구적 약학적 조성물로서,
여기서 상기 조성물은: (a) 15mg 내지 45mg의 디클로페낙 화합물; 및 (b) 베타-사이클로덱스트린 화합물을 포함하고;
여기서 디클로페낙 화합물의 복용량은 일일당 1.3mg/kg보다 적고; 그리고
여기서 상기 조성물은 비쥬얼 아날로그 스케일에 의해 분석된 적어도 82%의 최대 관찰 가능한 전체 통증 완화를 달성하는 비경구적 약학적 조성물" - 제 1항에 있어서,
상기 디클로페낙 화합물은 디클로페낙 소디움임을 특징으로 하는 비경구적 약학적 조성물. - 제 1항에 있어서,
상기 약학적 조성물은 정맥 내로 투여됨을 특징으로 하는 비경구적 약학적 조성물. - 제 1항에 있어서,
상기 디클로페낙 화합물의 복용량은 15mg 내지 22.5mg임을 특징으로 하는 비경구적 약학적 조성물. - 제 1항에 있어서,
상기 디클로페낙 화합물의 복용량은 30mg 내지 45mg임을 특징으로 하는 비경구적 약학적 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78648606P | 2006-03-28 | 2006-03-28 | |
US60/786,486 | 2006-03-28 | ||
PCT/US2007/064678 WO2007112272A2 (en) | 2006-03-28 | 2007-03-22 | Formulations of low dose diclofenac and beta-cyclodextrin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020147007290A Division KR20140038575A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020167006852A Division KR20160033796A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20150050595A true KR20150050595A (ko) | 2015-05-08 |
Family
ID=38541808
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087024795A Ceased KR20080112285A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020167006852A Ceased KR20160033796A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020147007290A Ceased KR20140038575A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020177031515A Ceased KR20170123724A (ko) | 2006-03-28 | 2007-03-22 | 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020157010213A Ceased KR20150050595A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087024795A Ceased KR20080112285A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020167006852A Ceased KR20160033796A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020147007290A Ceased KR20140038575A (ko) | 2006-03-28 | 2007-03-22 | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
KR1020177031515A Ceased KR20170123724A (ko) | 2006-03-28 | 2007-03-22 | 저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형 |
Country Status (12)
Country | Link |
---|---|
US (4) | US8580954B2 (ko) |
EP (3) | EP2004203A4 (ko) |
JP (3) | JP5823093B2 (ko) |
KR (5) | KR20080112285A (ko) |
CN (2) | CN102846585A (ko) |
AU (1) | AU2007230716B2 (ko) |
BR (1) | BRPI0709409A2 (ko) |
CA (1) | CA2647348A1 (ko) |
IL (2) | IL194185A (ko) |
MX (1) | MX2008012495A (ko) |
WO (1) | WO2007112272A2 (ko) |
ZA (1) | ZA200808115B (ko) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2003970A4 (en) * | 2006-03-28 | 2012-07-11 | Javelin Pharmaceuticals Inc | FORMULATIONS OF NON-STEROID ANTI-INFLAMMATORY DRUGS WITH LOW DOSE AND BETA-CYCLODEXTRIN |
WO2007112272A2 (en) | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
WO2009052454A2 (en) | 2007-10-19 | 2009-04-23 | University Of California | Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
JP6194248B2 (ja) | 2010-10-28 | 2017-09-06 | パシラ ファーマシューティカルズ インコーポレーテッド | 非ステロイド性抗炎症薬の徐放性処方物 |
EP2734212B1 (en) * | 2011-07-20 | 2017-09-06 | Hospira, Inc. | Compositions comprising diclofenac for the treatment of post-operative pain |
US20140275261A1 (en) | 2013-03-15 | 2014-09-18 | Dr. Reddy's Laboratories, Inc. | Diclofenac parenteral compositions |
CN107126418B (zh) * | 2016-02-25 | 2020-05-29 | 江苏思邈医药科技有限公司 | 供注射用双氯芬酸钠药物组合物及其制备方法 |
EP3541815A4 (en) | 2016-11-18 | 2020-07-15 | Pacira Pharmaceuticals, Inc. | ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME |
US11110073B2 (en) | 2017-03-24 | 2021-09-07 | Cadila Healthcare Limited | Storage stable aqueous injectable solution comprising diclofenac |
GB201720992D0 (en) * | 2017-12-15 | 2018-01-31 | Hooper Mark | A medical use |
WO2021048748A1 (en) | 2019-09-09 | 2021-03-18 | Ftf Pharma Private Limited | Pharmaceutical formulations comprising diclofenac |
US11707443B2 (en) | 2019-09-26 | 2023-07-25 | Rk Pharma Inc. | Storage stable aqueous parenteral solutions comprising diclofenac |
US20240382597A1 (en) * | 2021-12-31 | 2024-11-21 | LIVIONEX, Inc. | Formulations of anti-inflammatory agents comprising msm with enhanced solubility in water |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5984821U (ja) | 1982-11-30 | 1984-06-08 | 日新電機株式会社 | 積層コイル |
JPS59188644A (ja) | 1983-04-09 | 1984-10-26 | Fuji Photo Film Co Ltd | 画像形成方法 |
US4727064A (en) | 1984-04-25 | 1988-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Pharmaceutical preparations containing cyclodextrin derivatives |
DE3446873A1 (de) | 1984-12-21 | 1986-07-10 | Merckle Gmbh | Fluessige diclofenac-zubereitungen |
GB8506792D0 (en) | 1985-03-15 | 1985-04-17 | Janssen Pharmaceutica Nv | Derivatives of y-cyclodextrin |
US5785989A (en) | 1985-05-01 | 1998-07-28 | University Utah Research Foundation | Compositions and methods of manufacturing of oral dissolvable medicaments |
US6407079B1 (en) | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
JPS62138437U (ko) | 1986-02-26 | 1987-09-01 | ||
YU43290B (en) * | 1986-11-13 | 1989-06-30 | Lek Tovarna Farmacevtskih | Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine |
JPH0616547Y2 (ja) | 1986-12-16 | 1994-05-02 | ヒゲタ醤油株式会社 | 諸味揚槽用濾布 |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
EP0335545B2 (en) | 1988-03-29 | 1998-09-23 | University Of Florida | Pharmaceutical formulations for parenteral use |
JP2575460B2 (ja) * | 1988-05-12 | 1997-01-22 | 東京田辺製薬株式会社 | ダナゾール−シクロデキストリン包接化合物 |
MY106598A (en) | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
IT1227626B (it) | 1988-11-28 | 1991-04-23 | Vectorpharma Int | Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione |
GB2230440B (en) | 1989-02-09 | 1993-05-19 | Sandoz Ltd | Novel cyclosporin galenic forms |
IT1241417B (it) | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
IT1243342B (it) | 1990-07-13 | 1994-06-10 | Farcon Ag | Composizioni farmaceutiche orali liquide ad attivita' antiinfiammatoria |
WO1992003122A1 (de) | 1990-08-24 | 1992-03-05 | Gregor Cevc | Präparat zur wirkstoffapplikation in kleinsttröpfchenform |
DE69231457T2 (de) | 1991-06-21 | 2001-05-23 | Takeda Chemical Industries Ltd | Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate |
DE4207922A1 (de) | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung |
IT1255522B (it) | 1992-09-24 | 1995-11-09 | Ubaldo Conte | Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita' |
US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
US5389681A (en) | 1992-10-22 | 1995-02-14 | Ciba-Geigy Corporation | Parenteral solutions for diclofenac salts |
IT1256386B (it) | 1992-11-13 | 1995-12-04 | Luigi Boltri | Composizioni farmaceutiche comprendenti un farmaco,una sostanza polimerica reticolata,un olio ed un agente tensioattivo |
JPH08511009A (ja) | 1993-06-08 | 1996-11-19 | チバ−ガイギー アクチェンゲゼルシャフト | ジクロフェナックを含有する経口固体剤形の製造方法 |
IT1264696B1 (it) | 1993-07-09 | 1996-10-04 | Applied Pharma Res | Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata |
US5866162A (en) | 1993-08-10 | 1999-02-02 | Smithkline Beecham P.L.C. | Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple |
GB9316580D0 (en) | 1993-08-10 | 1993-09-29 | Smithkline Beecham Plc | Pharmaceutical composition |
GB9318880D0 (en) | 1993-09-11 | 1993-10-27 | Smithkline Beecham Plc | Pharmaceutical composition |
IL111184A (en) * | 1993-10-08 | 2000-08-13 | Farmarc Nederland B V Of Cito | Crystalline inclusion complex of diclofenac with unsubstituted beta-cyclodextrin |
US5540930A (en) | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
DE69432186T2 (de) | 1993-11-18 | 2004-05-06 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung stabiler arzneimittel |
ZA949182B (en) * | 1993-12-02 | 1995-07-26 | South African Druggists Ltd | Pharmaceutical composition |
US5464633A (en) | 1994-05-24 | 1995-11-07 | Jagotec Ag | Pharmaceutical tablets releasing the active substance after a definite period of time |
WO1995032737A1 (en) | 1994-05-27 | 1995-12-07 | Farmarc Nederland Bv | Pharmaceutical composition |
EP0785780A1 (en) | 1994-10-10 | 1997-07-30 | Novartis AG | Ophthalmic and aural compositions containing diclofenac potassium |
ZA959469B (en) * | 1994-11-15 | 1996-05-15 | South African Druggists Ltd | Pharmaceutical composition |
WO1996022088A1 (en) | 1995-01-20 | 1996-07-25 | Wakamoto Pharmaceutical Co., Ltd. | Anti-inflammatory eyedrops |
JP3934705B2 (ja) * | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | サイクロデキストリン組成物 |
US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
US5821237A (en) | 1995-06-07 | 1998-10-13 | The Procter & Gamble Company | Compositions for visually improving skin |
IT1276689B1 (it) | 1995-06-09 | 1997-11-03 | Applied Pharma Res | Forma farmaceutica solida ad uso orale |
AU5774796A (en) | 1995-06-13 | 1997-01-09 | Dyer, Alison Margaret | Pharmaceutical compositions containing lornoxicam and cyclod extrin |
TW434023B (en) * | 1995-09-18 | 2001-05-16 | Novartis Ag | Preserved ophthalmic composition |
HUP9600758A2 (en) | 1996-03-27 | 1998-03-02 | Cyclolab Ciklodextrin Kutato F | Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption |
FR2751875B1 (fr) | 1996-08-05 | 1998-12-24 | Scr Newpharm | Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation |
EP0868915A1 (en) | 1997-04-02 | 1998-10-07 | Panacea Biotec Limited | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium |
IT1291362B1 (it) | 1997-05-13 | 1999-01-07 | Vectorpharma Int | Composizioni farmaceutiche multicomponente bifasiche contenenti sostanze atte a modificare la partizione dei principi attivi |
JP2002509103A (ja) | 1998-01-20 | 2002-03-26 | アプライド・アナリティカル・インダストリーズ,インコーポレイテッド | 経口液体組成物 |
US6365180B1 (en) | 1998-01-20 | 2002-04-02 | Glenn A. Meyer | Oral liquid compositions |
US7772220B2 (en) | 2004-10-15 | 2010-08-10 | Seo Hong Yoo | Methods and compositions for reducing toxicity of a pharmaceutical compound |
US6365182B1 (en) * | 1998-08-12 | 2002-04-02 | Cima Labs Inc. | Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US7186260B2 (en) | 1999-04-29 | 2007-03-06 | Hyson Morton I | Medicated wrap |
US6313370B1 (en) | 1999-04-29 | 2001-11-06 | Morton Hyson | Medicated wrap |
SV2002000055A (es) * | 1999-04-30 | 2002-07-03 | Lilly Icos Llc | Articulos de manufactura ref. n0. 29342/36212 sv |
EP1185251A1 (en) | 1999-05-24 | 2002-03-13 | Purepac Pharmaceutical Co. | A pharmaceutical composition containing an active agent that is maintained in solid amorphous form and method of making the same |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
SK12672001A3 (sk) | 1999-12-08 | 2002-04-04 | Pharmacia Corporation | Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku |
KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
AU4866001A (en) | 2000-03-28 | 2001-10-08 | Farmarc Nederland Bv | Alprazolam inclusion complexes and pharmaceutical compositions thereof |
AU2001259816A1 (en) | 2000-06-22 | 2002-01-02 | Advanced Medecine, Inc. | Polyhydroxy glycopeptide derivatives |
PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
KR20030043955A (ko) | 2000-09-08 | 2003-06-02 | 파마시아 이탈리아 에스.피.에이. | 화학적 예방제로서 엑스메스탄 |
EP1219304B1 (de) | 2000-12-28 | 2004-10-20 | Fresenius Kabi Austria GmbH | Stabile Infusionslösung von Diclofenac-Salzen, deren Herstellung und Verwendung |
EP1219306A1 (en) | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
MXPA03006607A (es) | 2001-01-26 | 2003-09-22 | Upjohn Co | Metodo combinado para tratar trastornos dependientes de hormonas. |
WO2002080159A1 (de) * | 2001-03-28 | 2002-10-10 | Bayer Aktiengesellschaft | Optischer datenträger enthaltend in der informationsschicht einen cyaninfarbstoff als lichtabsorbierende verbindung |
US20080220441A1 (en) | 2001-05-16 | 2008-09-11 | Birnbaum Eva R | Advanced drug development and manufacturing |
US20040137062A1 (en) | 2001-05-25 | 2004-07-15 | Sham Chopra | Chronotherapy tablet and methods related thereto |
SE0102855D0 (sv) | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | Method of treatment |
FR2830017B1 (fr) | 2001-09-27 | 2005-11-04 | Centre Nat Rech Scient | Materiau compose d'au moins un polymere biodegradable et de cyclodextrines |
CA2463687A1 (en) | 2001-10-18 | 2003-04-24 | Decode Genetics Ehf | Cyclodextrin complexes |
FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
NZ534598A (en) | 2002-02-01 | 2004-11-26 | Shimoda Biotech Pty Ltd | Pharmaceutical composition |
EP1476135A1 (en) | 2002-02-22 | 2004-11-17 | Pharmacia Corporation | Ophthalmic formulation with gum system |
US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
CN1232539C (zh) * | 2002-05-10 | 2005-12-21 | 刘云清 | 有机药物与倍他环糊精衍生物的配合物及其制备方法 |
WO2003097011A1 (en) | 2002-05-17 | 2003-11-27 | Eisai Co., Ltd. | Compositions and methods using proton pump inhibitors |
DK1515729T3 (da) | 2002-06-13 | 2008-06-16 | Novartis Ag | Kvaterniserede ammoniumcyclodextrinforbindelser |
FR2842736B1 (fr) | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
US7148211B2 (en) | 2002-09-18 | 2006-12-12 | Genzyme Corporation | Formulation for lipophilic agents |
NZ540318A (en) | 2002-10-31 | 2007-09-28 | Umd Inc | Therapeutic compositions for drug delivery to and through covering epithelia |
MXPA05005587A (es) | 2002-11-27 | 2005-07-27 | Pharmacia Corp | Composicion liquida concentrada de valdecoxib. |
KR100972777B1 (ko) | 2003-01-27 | 2010-08-03 | 비타민 씨60 바이오리서치 가부시키가이샤 | 항산화 조성물과 외용 조성물 |
NZ541750A (en) | 2003-02-19 | 2008-11-28 | Rinat Neuroscience Corp | Use of an anti-nerve growth factor antibody and an NSAID for the preparation of a medicament for treating pain |
JP2007525429A (ja) | 2003-03-11 | 2007-09-06 | キューエルティー ユーエスエー,インコーポレイテッド. | 細胞スケジュール依存性抗癌剤のための処方 |
US20070049552A1 (en) | 2003-04-14 | 2007-03-01 | Babu Manoj M | Fluoroquinolone formulations and methods of making and using the same |
US20050085446A1 (en) | 2003-04-14 | 2005-04-21 | Babu M.K. M. | Fluoroquinolone formulations and methods of making and using the same |
TW575271U (en) * | 2003-06-25 | 2004-02-01 | Wen-Chin Fan | Three-dimensional picture exhibiting device of image display |
US20050197303A1 (en) | 2003-10-31 | 2005-09-08 | Bausch & Lomb Incorporated | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
US20050095205A1 (en) | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
WO2005042026A1 (ja) | 2003-10-31 | 2005-05-12 | Wakamoto Pharmaceutical Co., Ltd. | 可逆性熱ゲル化水性組成物 |
EP1734936B1 (en) | 2004-01-30 | 2014-09-10 | Rutgers, The State University | Amphiphilic star-like or scoprion-like macromolecules, various compositions and uses thereof |
KR20050081092A (ko) | 2004-02-12 | 2005-08-18 | 한국과학기술연구원 | 생체적합성 친수성 고분자를 포함하는 콜로이드계 조성물,제형 및 이들의 제조 방법 |
ATE454905T1 (de) | 2004-03-10 | 2010-01-15 | Shimoda Biotech Pty Ltd | Stabile injizierbare diclofenac- zubereitungen |
US20050203115A1 (en) | 2004-03-10 | 2005-09-15 | Sancilio Frederick D. | Narcotic-NSAID ion pairs |
DE102004017351A1 (de) * | 2004-04-08 | 2005-10-27 | Kalle Gmbh | Schlauchförmige Nahrungsmittelhülle mit übertragbarer Innenschicht |
WO2005120578A2 (en) | 2004-06-07 | 2005-12-22 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
CA2570389A1 (en) | 2004-06-17 | 2005-12-29 | Osteologix A/S | Treatments comprising strontium for rheumatic and arthritic diseases and pain |
ITMI20041245A1 (it) | 2004-06-22 | 2004-09-22 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche iniettabnili comprendenti diclofenac sodico e b-ciclodestrina |
TWI279226B (en) | 2004-07-20 | 2007-04-21 | Schoeller Textil Ag | Dressings which can be applied several times to textile fibres and textile fabrics |
GB2417900A (en) | 2004-09-11 | 2006-03-15 | Medway Science Technologies Lt | Composition for oral drug delivery |
BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
KR20070084211A (ko) | 2004-10-15 | 2007-08-24 | 유서홍 | 약제학적 화합물의 독성을 감소시키기 위한 방법 및 조성물 |
EP1848541A4 (en) | 2005-02-07 | 2013-01-16 | Pharmalight Inc | METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS |
US7140694B2 (en) * | 2005-03-29 | 2006-11-28 | Steven Mason | Wheel spoke adjuster guard |
KR101255650B1 (ko) * | 2005-05-04 | 2013-04-16 | 프로노바 바이오파마 너지 에이에스 | 새로운 dha 유도체 및 약제로서의 용도 |
TW200745160A (en) | 2005-06-30 | 2007-12-16 | Abbott Lab | IL-12/P40 binding proteins |
AU2006264407B2 (en) | 2005-07-04 | 2012-08-30 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
US9198862B2 (en) | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
WO2007061828A2 (en) | 2005-11-21 | 2007-05-31 | Schering-Plough Ltd. | Pharmaceutical compositions comprising buprenorphine |
EP3263117A1 (en) | 2005-11-28 | 2018-01-03 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
JP5196130B2 (ja) | 2005-12-27 | 2013-05-15 | ライオン株式会社 | ソフトコンタクトレンズ用組成物及び吸着抑制方法 |
US20070207222A1 (en) | 2006-03-01 | 2007-09-06 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
US9192644B2 (en) | 2006-03-06 | 2015-11-24 | The Regents Of The University Of California | Bioavailable curcuminoid formulations for treating Alzheimer's disease and other age-related disorders |
US7767217B2 (en) | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
EP2003970A4 (en) | 2006-03-28 | 2012-07-11 | Javelin Pharmaceuticals Inc | FORMULATIONS OF NON-STEROID ANTI-INFLAMMATORY DRUGS WITH LOW DOSE AND BETA-CYCLODEXTRIN |
WO2007112272A2 (en) | 2006-03-28 | 2007-10-04 | Javelin Pharmaceuticals, Inc. | Formulations of low dose diclofenac and beta-cyclodextrin |
WO2008006216A1 (en) | 2006-07-14 | 2008-01-17 | Mistral Pharma, Inc. | Anti-inflammatory and cytoprotectant chronotherapy |
SMT202000607T1 (it) | 2006-09-08 | 2021-01-05 | Abbvie Bahamas Ltd | Proteine leganti l'interleuchina-13 |
MX2009003372A (es) | 2006-10-02 | 2009-09-24 | Labtec Gmbh | Formas de dosificacion de pelicula no mucoadhesiva. |
JP5143841B2 (ja) | 2006-10-10 | 2013-02-13 | ロス アラモス ナショナル セキュリティー,エルエルシー | 高度な薬物開発及び製造 |
FI20065800A0 (fi) | 2006-12-13 | 2006-12-13 | Glykos Finland Oy | Polyvalentit biokonjugaatit |
EP2465506A1 (en) | 2006-12-18 | 2012-06-20 | Allergan, Inc. | Methods and compositions for treating gastrointestinal disorders |
AU2007335262A1 (en) | 2006-12-21 | 2008-06-26 | The University Of Western Australia | Method for coating nanoparticles |
WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
EP1974751A1 (en) | 2007-03-26 | 2008-10-01 | The Jordanian Pharmaceutical Manufacturing Co. | Formulations for non-steroidal anti-inflammatory drugs |
WO2008133982A2 (en) | 2007-04-27 | 2008-11-06 | Lectec Corporation | Adhesive patch with aversive agent |
KR101753131B1 (ko) | 2007-04-27 | 2017-07-04 | 사이덱스 파마슈티칼스, 인크. | 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법 |
US7662858B2 (en) | 2008-05-23 | 2010-02-16 | Aaipharma, Inc. | Method of treating post-surgical acute pain |
EP2734212B1 (en) * | 2011-07-20 | 2017-09-06 | Hospira, Inc. | Compositions comprising diclofenac for the treatment of post-operative pain |
-
2007
- 2007-03-22 WO PCT/US2007/064678 patent/WO2007112272A2/en active Application Filing
- 2007-03-22 AU AU2007230716A patent/AU2007230716B2/en not_active Ceased
- 2007-03-22 EP EP07759156A patent/EP2004203A4/en not_active Ceased
- 2007-03-22 US US11/689,931 patent/US8580954B2/en not_active Expired - Fee Related
- 2007-03-22 KR KR1020087024795A patent/KR20080112285A/ko not_active Ceased
- 2007-03-22 EP EP20120164658 patent/EP2522344A1/en not_active Withdrawn
- 2007-03-22 KR KR1020167006852A patent/KR20160033796A/ko not_active Ceased
- 2007-03-22 BR BRPI0709409-4A patent/BRPI0709409A2/pt not_active Application Discontinuation
- 2007-03-22 KR KR1020147007290A patent/KR20140038575A/ko not_active Ceased
- 2007-03-22 KR KR1020177031515A patent/KR20170123724A/ko not_active Ceased
- 2007-03-22 CN CN201210342041XA patent/CN102846585A/zh active Pending
- 2007-03-22 CN CNA2007800115094A patent/CN101410123A/zh active Pending
- 2007-03-22 KR KR1020157010213A patent/KR20150050595A/ko not_active Ceased
- 2007-03-22 EP EP20120164654 patent/EP2522343A1/en not_active Withdrawn
- 2007-03-22 CA CA 2647348 patent/CA2647348A1/en not_active Abandoned
- 2007-03-22 JP JP2009503166A patent/JP5823093B2/ja not_active Expired - Fee Related
- 2007-03-22 MX MX2008012495A patent/MX2008012495A/es active IP Right Grant
-
2008
- 2008-09-17 IL IL194185A patent/IL194185A/en not_active IP Right Cessation
- 2008-09-22 ZA ZA2008/08115A patent/ZA200808115B/en unknown
-
2011
- 2011-05-12 US US13/106,697 patent/US8946292B2/en active Active
-
2012
- 2012-10-14 IL IL222432A patent/IL222432A/en not_active IP Right Cessation
-
2013
- 2013-10-10 US US14/051,021 patent/US20140107209A1/en not_active Abandoned
- 2013-10-17 JP JP2013216668A patent/JP6157305B2/ja not_active Expired - Fee Related
-
2014
- 2014-12-19 US US14/576,404 patent/US20150105467A1/en not_active Abandoned
-
2015
- 2015-12-10 JP JP2015241131A patent/JP6265964B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20150050595A (ko) | 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형 | |
AU2007230718B2 (en) | Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin | |
JP6353577B2 (ja) | 組み合わせ組成物 | |
KR102656841B1 (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
CA2704430C (en) | Injectable meclizine formulations and methods | |
AU2012209035B9 (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
CN114423458A (zh) | 含有对二羟硼基苯丙氨酸的注射液剂 | |
HK1180247A (en) | Formulations of low dose diclofenac and beta-cyclodextrin | |
BR112021009365A2 (pt) | formulação de glicocorticoide estável | |
TW200838534A (en) | Treatment for irritable bowel syndrome | |
Qian et al. | Effects of intraperitoneal (IP) different doses of ketamine on cognitive function in aged rats: 9AP6-8 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20150421 Application number text: 1020147007290 Filing date: 20140319 |
|
PA0201 | Request for examination | ||
A302 | Request for accelerated examination | ||
PA0302 | Request for accelerated examination |
Patent event date: 20150429 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
PG1501 | Laying open of application | ||
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20150721 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20151119 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20150721 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20160219 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20151119 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20160601 Appeal identifier: 2016101000958 Request date: 20160219 |
|
PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20160315 Application number text: 1020147007290 Filing date: 20140319 |
|
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20160315 Patent event code: PA01071R01D Filing date: 20140319 Application number text: 1020147007290 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20160219 Effective date: 20160601 |
|
PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20160601 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20160219 Decision date: 20160601 Appeal identifier: 2016101000958 |